Abstract
Background: Fungal secondary metabolites are important sources for the discovery of new pharmaceuticals, as exemplified by penicillin, lovastatin and cyclosporine. Searching for secondary metabolites of the fungi Metarhizium spp., we previously identified tyrosine betaine as a major constituent.
Methods: Because of the structural similarity with other inhibitors of neprilysin (NEP), an enzyme explored for the treatment of heart failure, we devised the synthesis of tyrosine betaine and three analogues to be subjected to in vitro NEP inhibition assays and to molecular modeling studies.
Results: In spite of the similar binding modes with other NEP inhibitors, these compounds only displayed moderate inhibitory activities (IC50 ranging from 170.0 to 52.9 µM). However, they enclose structural features required to hinder passive blood brain barrier permeation (BBB).
Conclusions: Tyrosine betaine remains as a starting point for the development of NEP inhibitors because of the low probability of BBB permeation and, consequently, of NEP inhibition at the Central Nervous System, which is associated to an increment in the Aβ levels and, accordingly, with a higher risk for the onset of Alzheimer's disease.
Keywords: Neprilysin, heart failure, tyrosine betaine, fungal metabolites, Metarhizium spp, blood brain barrier.
Current Pharmaceutical Design
Title:Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Volume: 24 Issue: 17
Author(s): Daniel Fabio Kawano*, Marcelo Rodrigues de Carvalho, Mauricio Ferreira Marcondes Machado, Adriana Karaoglanovic Carmona, Gilberto Ubida Leite Braga and Ivone Carvalho
Affiliation:
- Faculty of Pharmaceutical Sciences, University of Campinas - UNICAMP, Rua Candido Portinari 200, 13083-871 Campinas-SP,Brazil
Keywords: Neprilysin, heart failure, tyrosine betaine, fungal metabolites, Metarhizium spp, blood brain barrier.
Abstract: Background: Fungal secondary metabolites are important sources for the discovery of new pharmaceuticals, as exemplified by penicillin, lovastatin and cyclosporine. Searching for secondary metabolites of the fungi Metarhizium spp., we previously identified tyrosine betaine as a major constituent.
Methods: Because of the structural similarity with other inhibitors of neprilysin (NEP), an enzyme explored for the treatment of heart failure, we devised the synthesis of tyrosine betaine and three analogues to be subjected to in vitro NEP inhibition assays and to molecular modeling studies.
Results: In spite of the similar binding modes with other NEP inhibitors, these compounds only displayed moderate inhibitory activities (IC50 ranging from 170.0 to 52.9 µM). However, they enclose structural features required to hinder passive blood brain barrier permeation (BBB).
Conclusions: Tyrosine betaine remains as a starting point for the development of NEP inhibitors because of the low probability of BBB permeation and, consequently, of NEP inhibition at the Central Nervous System, which is associated to an increment in the Aβ levels and, accordingly, with a higher risk for the onset of Alzheimer's disease.
Export Options
About this article
Cite this article as:
Kawano Fabio Daniel *, de Carvalho Rodrigues Marcelo , Machado Ferreira Marcondes Mauricio , Carmona Karaoglanovic Adriana , Braga Ubida Leite Gilberto and Carvalho Ivone , Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure, Current Pharmaceutical Design 2018; 24 (17) . https://dx.doi.org/10.2174/1381612824666180515114236
DOI https://dx.doi.org/10.2174/1381612824666180515114236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diastolic Heart Failure and LV Dyssynchrony
Current Pharmaceutical Biotechnology Optimal Medical Therapy for Coronary Artery Disease in 2011 – Perspectives from the STICH Trial
Cardiovascular & Hematological Agents in Medicinal Chemistry Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Efficacy of Topical Formulations in Healing of Caesarean Scars Using Non-Invasive Devices: A Controlled Trial
Applied Drug Research, Clinical Trials and Regulatory Affairs Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Ion Channels and Epilepsy
Current Pharmaceutical Design Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users
Current Drug Safety Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Patent Selections
Recent Patents on Medical Imaging Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Synthesis and Biological Evaluation of Diaryl Ether Linked DC-81 Conjugates as Potential Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry The Molecular Targets of Cannabinoids in the Treatment of Cancer and Inflammation
Current Pharmaceutical Design